Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley

Morgan Stanley analyst Michael Ulz raised the price target on Vir Biotechnology (NASDAQ: VIR) to $15.00 (from $12.00) while maintaining a Equalweight rating.

The analyst comments "Updated, preliminary results from the Ph2 SOLSTICE study in hepatitis delta (HDV) confirm robust and durable antiviral activity, while importantly, rates of ALT normalization improved. Of note, mgt. is focused on quickly advancing into Ph3 and remains on track to meet with the FDA in 3Q24."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Apollo Hospitals (APLH:IN) PT Raised to INR8,500 at ICICI Securities
• LG Electronics India (LGEL:IN) PT Raised to INR1,815 at ICICI Securities